This analysis examines the historical and forecast performance for AstraZeneca in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
Benchmark AstraZeneca’s performance against key rivals in the ethical pharmaceutical sector
Analyze how AstraZeneca has overcome generic erosion to omeprazole positioning itself to outperform the Big Pharma peer set in sales growth to 2011
Assess how AstraZeneca will continue to generate sales in the low-growth GI, CV, CNS and respiratory markets, bucking the Big Pharma trend
